| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Michael D Ward | |
| Jeffrey D Rimer | |||
| Ann M Kolbach-Mandel | |||
| Jeffrey A Wesson | |||
| P2860 | cites work | Nephrolithiasis: molecular mechanism of renal stone formation and the critical role played by modulators | Q27027510 |
| Phosphorylation of osteopontin peptides mediates adsorption to and incorporation into calcium oxalate crystals | Q28291901 | ||
| Biomimetic model systems for investigating the amorphous precursor pathway and its role in biomineralization | Q28704095 | ||
| Inhibition of calcium oxalate crystal growth and aggregation by prothrombin and its fragments in vitro: relationship between protein structure and inhibitory activity. | Q30322820 | ||
| Inhibitors of stone formation. | Q30425662 | ||
| Reproducible imaging and dissection of plasmid DNA under liquid with the atomic force microscope | Q30783745 | ||
| Adhesion at calcium oxalate crystal surfaces and the effect of urinary constituents | Q33722896 | ||
| Rice-bran products: phytonutrients with potential applications in preventive and clinical medicine. | Q34200719 | ||
| Polynucleotide adsorption to negatively charged surfaces in divalent salt solutions. | Q34354056 | ||
| A current understanding of vascular calcification in CKD. | Q34355897 | ||
| 2D map of proteins from human renal stone matrix and evaluation of their effect on oxalate induced renal tubular epithelial cell injury | Q34620181 | ||
| Diversity in protein profiles of individual calcium oxalate kidney stones | Q34849855 | ||
| Peeping into human renal calcium oxalate stone matrix: characterization of novel proteins involved in the intricate mechanism of urolithiasis | Q34874834 | ||
| Calcium oxalate monohydrate aggregation induced by aggregation of desialylated Tamm-Horsfall protein | Q35050995 | ||
| The amount and nature of the organic matrix in urinary calculi: a review | Q35238150 | ||
| Modulators of urinary stone formation | Q35672755 | ||
| Exploring calcium oxalate crystallization: a constant composition approach | Q36070242 | ||
| Stone analysis | Q36396134 | ||
| Crystal retention in renal stone disease: a crucial role for the glycosaminoglycan hyaluronan? | Q36481372 | ||
| Protein regulation of intrarenal crystallization | Q36507228 | ||
| Role of crystal surface adhesion in kidney stone disease | Q36507236 | ||
| Effects of human urine on aggregation of calcium oxalate crystals | Q69991109 | ||
| Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis | Q70133657 | ||
| Activity products in stone-forming and non-stone-forming urine | Q72081757 | ||
| Organic matrix of human urinary concretions | Q72127629 | ||
| Role of anionic proteins in kidney stone formation: interaction between model anionic polypeptides and calcium oxalate crystals | Q73593564 | ||
| Interpolyelectrolyte and block ionomer complexes for gene delivery: physico-chemical aspects | Q73850328 | ||
| Present concepts concerning the origin of matrix and stones | Q76453166 | ||
| Formation of hydrated calcium oxalates in the presence of poly-L-aspartic acid | Q77546800 | ||
| Electrophoretic separation and characterization of urinary glycosaminoglycans and their roles in urolithiasis | Q79403962 | ||
| Crystallographic analysis of urinary calculi: a 23-year survey study | Q79656551 | ||
| Comparison of matrix proteins in different types of urinary stone by proteomic analysis using liquid chromatography-tandem mass spectrometry | Q83860541 | ||
| Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins | Q93533841 | ||
| Molecular modulation of calcium oxalate crystallization | Q36643385 | ||
| Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily | Q36778774 | ||
| Effect of Tamm-Horsfall protein on calcium oxalate precipitation | Q36796627 | ||
| Phosphorylation of osteopontin is required for inhibition of calcium oxalate crystallization | Q37345818 | ||
| Acidic macromolecules of mineralized tissues: the controllers of crystal formation | Q37407174 | ||
| Use of traditional Chinese medicine in the management of urinary stone disease | Q37589745 | ||
| Tuning calcite morphology and growth acceleration by a rational design of highly stable protein-mimetics | Q37743897 | ||
| Biomolecular mechanism of urinary stone formation involving osteopontin | Q38057623 | ||
| Gist of medicinal plants of Pakistan having ethnobotanical evidences to crush renal calculi (kidney stones). | Q38208020 | ||
| Proteomic study of renal uric acid stone | Q38497552 | ||
| Protein inhibitors of crystal growth | Q38603734 | ||
| Physiological conditions can be reflected in human urine proteome and metabolome | Q38608509 | ||
| Uromucoids and urinary stone formation | Q39544590 | ||
| Physiopathologic aspects of Tamm-Horsfall protein: a phylogenetically conserved marker of the thick ascending limb of Henle's loop | Q39593113 | ||
| Glycosaminoglycans as inhibitors of stone formation | Q39667111 | ||
| The molecular theory of polyelectrolyte solutions with applications to the electrostatic properties of polynucleotides | Q39750514 | ||
| Adsorption of DNA to mica mediated by divalent counterions: a theoretical and experimental study. | Q40256508 | ||
| An acidic peptide sequence of nucleolin-related protein can mediate the attachment of calcium oxalate to renal tubule cells | Q40530146 | ||
| Tamm-Horsfall glycoprotein and calcium nephrolithiasis. | Q40546475 | ||
| Annexin II is present on renal epithelial cells and binds calcium oxalate monohydrate crystals | Q40675893 | ||
| Regulation of renal epithelial cell affinity for calcium oxalate monohydrate crystals | Q40902061 | ||
| Acidic peptide and polyribonucleotide crystal growth inhibitors in human urine | Q41057095 | ||
| Surface exposure of phosphatidylserine increases calcium oxalate crystal attachment to IMCD cells | Q41141403 | ||
| Osteopontin at mineralized tissue interfaces in bone, teeth, and osseointegrated implants: ultrastructural distribution and implications for mineralized tissue formation, turnover, and repair | Q41142551 | ||
| Glycosaminoglycans, proteins, and stone formation: adult themes and child's play | Q41193178 | ||
| Proteins of human urine. I. Concentration and analysis by two-dimensional electrophoresis | Q41675650 | ||
| Proteome of human calcium kidney stones | Q42937433 | ||
| Inflammatory and fibrotic proteins proteomically identified as key protein constituents in urine and stone matrix of patients with kidney calculi | Q43590972 | ||
| Increased calcium oxalate crystal nucleation and aggregation by peroxidized protein of human kidney stone matrix and renal cells | Q43693581 | ||
| The calcium oxalate crystal growth inhibitor protein produced by mouse kidney cortical cells in culture is osteopontin | Q44184044 | ||
| Aggregation and dispersion characteristics of calcium oxalate monohydrate: effect of urinary species | Q44264965 | ||
| Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules | Q44265632 | ||
| Specificity of growth inhibitors and their cooperative effects in calcium oxalate monohydrate crystallization | Q44834447 | ||
| Probing crystallization of calcium oxalate monohydrate and the role of macromolecule additives with in situ atomic force microscopy | Q45067118 | ||
| Urinary tract stone disease in the United States veteran population. II. Geographical analysis of variations in composition | Q45336657 | ||
| Crystal-matrix relationships in experimentally induced urinary calcium oxalate monohydrate crystals, an ultrastructural study | Q45774232 | ||
| Control of calcium oxalate crystal growth by face-specific adsorption of an osteopontin phosphopeptide | Q46278809 | ||
| Modulation of calcium oxalate crystallization by linear aspartic acid-rich peptides | Q46281314 | ||
| Role of phosphate groups in inhibition of calcium oxalate crystal growth by osteopontin | Q46428921 | ||
| Regulation by macromolecules of calcium oxalate crystal aggregation in stone formers | Q46466794 | ||
| Renal calcinosis and stone formation in mice lacking osteopontin, Tamm-Horsfall protein, or both | Q46980085 | ||
| Natural promoters of calcium oxalate monohydrate crystallization. | Q53474547 | ||
| Fuzzy Nanoassemblies: Toward Layered Polymeric Multicomposites | Q55966433 | ||
| Calibration of atomic‐force microscope tips | Q56639767 | ||
| Phase behaviour and complex coacervation of aqueous polypeptide solutions | Q56673797 | ||
| Layer-by-layer engineered capsules and their applications | Q57645399 | ||
| Modifiers of calcium oxalate crystallization found in urine. III. Studies on the role of Tamm-Horsfall mucoprotein and of ionic strength | Q69573996 | ||
| P433 | issue | 1 | |
| P921 | main subject | macromolecule | Q178593 |
| P304 | page(s) | 57-74 | |
| P577 | publication date | 2016-12-02 | |
| P1433 | published in | Urolithiasis | Q27724667 |
| P1476 | title | The role of macromolecules in the formation of kidney stones | |
| P478 | volume | 45 |
| Q54945958 | Anti-Transforming Growth Factor β IgG Elicits a Dual Effect on Calcium Oxalate Crystallization and Progressive Nephrocalcinosis-Related Chronic Kidney Disease. |
| Q90263765 | Cystinuria: genetic aspects, mouse models, and a new approach to therapy |
| Q39024110 | Do "inhibitors of crystallisation" play any role in the prevention of kidney stones? A critique |
| Q51736287 | Electron probe micro-analysis reveals the complexity of mineral deposition mechanisms in urinary stones. |
| Q91933004 | Hydroxyl-rich macromolecules enable the bio-inspired synthesis of single crystal nanocomposites |
| Q53430569 | Influences of Crystal Anisotropy in Pharmaceutical Process Development. |
| Q38896942 | Stone former urine proteome demonstrates a cationic shift in protein distribution compared to normal |
Search more.